bpc 157 pharmacokinetics half life study BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers BPC-157 and Its Novel Hybrid
Description
Intradural disc a diagnostic dilemma: case series and review of literature
[DOI] [PubMed] [Google Scholar] 5.Allen LH, Rosado JL, Casterline JE, Lopez P, Muoz E, Garcia OP, Martinez H
These bispecific constructs, characterized by their small size, high solubility and extended half-life facilitated by the integration of an albumin-specific sdAb, have demonstrated potent cytotoxicity against tumor cells, exceeding the ADCC of Daratumumab [94]
This will not only prevent further deterioration but also potentially aid in the repair of existing damage
